

# STATISTICAL REVIEW

## Patients Registered in 2012

MEDICAL STATISTICS UNIT  
NATIONAL CANCER INSTITUTE  
MAHARAGAMA

Volume 8



## Foreword

The National Cancer Institute of Sri Lanka is the premier cancer treatment centre out of the nine centers attached to the Teaching and Provincial General Hospitals of Sri Lanka. The NCI provides its services to over 50,000 inward patients which include more than 10,000 new registrations annually coming from various areas of the country. Out of these new registrations, patients identified as malignant are being managed with specialized treatments.

The **Statistical Review –Patients Registered in 2012** is the 8<sup>th</sup> publication in the series started in 2006 contains data of cancer patients registered at National Cancer Institute Sri Lanka in 2012. The aim of this publication is to become a standard institutional cancer registry by providing accurate statistical data which is essential for clinicians, health administrators, researchers, policy makers and strategists in cancer related field.

I wish to express my gratitude to the Director, Dr.M.Y.K.Wilfred, Deputy Director, Dr.Buddhika Kurukulasooriya, and all Consultants for the valuable suggestions, encouragements, guidance and appreciation given for the improvement of this publication.

I am also grateful to the staff of the Medical Records & Statistics Unit for their support and assistance to make this venture a success.

We welcome your comments & valuable suggestions for further improvement of this annual publication.

Dr. L.D.Rathnasiri, (RMO)

Medical Statistics Unit.

email- [statistics@ncisl.lk](mailto:statistics@ncisl.lk), [rmoncig2@gmail.com](mailto:rmoncig2@gmail.com)

August 2017

## *INDEX*

	Page No
Introduction to National Cancer Institute, Sri Lanka	2
Classification of Diseases of Patients Registered at NCI in 2012	3
Classification by Site of Malignancy & ICD code	4
Leading Cancer sites by Sex & Age groups	13
Indoor Mortality Statistics of NCI	14
Survival by Sex and Leading Cancer sites	15
Cancer Patients reported to NCI by district	19
Cancer patients reported to NCI during last three years by District	20

## **Introduction to National Cancer Institute, Sri Lanka.**

The National Cancer Institute (NCI) is a teaching hospital, managed under supervision of the Ministry of Health Sri Lanka. It is the premium hospital dedicated to diagnose, treat and follow-up of cancer patients in Sri Lanka, located at Maharagama, 16 km away from Colombo, the capital of Sri Lanka.

It was first established as a radiotherapy unit with inward facilities in 1956 and now it has developed into a tertiary care hospital with modern screening, diagnostic, & treatment facilities.

NCI, which spreads over 10 acres, provides patient care approximately 172000 outdoor patients and 60000 indoor patients per year with 26 wards consist of 873 beds. Thirty seven Consultants, Post graduate trainees, Medical Officers, and more than thousand health workers including nurses, pharmacists, radiographers, MLTs provide their service under the guidance of Director. Consultant Oncologists, Oncosurgeons, Oncogynaecologists, Physicians, conduct outdoor clinics daily to follow up patients with malignancies by the help of all range of Hematological, Histopathological, Microbiological, and Radiological investigations under the supervision of respective consultants.

Medical, Onco-surgical, bone marrow transplant, and all kinds of radiological treatment methods including Mega voltage photon & electron therapy, Brachytherapy, and Iodine therapy, are given free of charge. Physiotherapy, Speech therapy, Counselling, Outdoor blood transfusion & Chemotherapy services are among the other services available in this hospital.

**Classification of Diseases of Patients registered  
at National Cancer Institute in 2012**

(These information are based on data available at NCI Maharagama)

	Total No	Female	Male
Total No of Malignancies (including CIN-111 & In Situ)	7539	4231	3308
No of Multiple primary cases	5	4	1
Total No of Pts with malignancies	7534	4227	3307
Total No of Pts for Screening & Non Malignant Conditions	2142	1893	249
Total No of CIN 1,11, & Uncertain Conditions	108	74	34
Total No of Thyrotoxicosis Pts	227	166	61
Unable to trace diagnosis (File Not available, Not clear)	2541	1612	929
Total no of patients registered	12552	7972	4580

**Leading Cancer sites of Females**

1	C-50 BREAST	1160
2	C-53 CERVIX UTERI	471
3	C-73 THYROID GLAND	442
4	C-56 OVARY	357
5	C-42 HAEMATOPOIETIC & R.E.SYSTEM	316
6	C-54 CORPUS UTERI	180
7	C-15 ESOPHAGUS	141
8	C-77 LYMPH NODES	118
9	C-20 RECTUM	92
10	C-34 BRONCHUS & LUNG	87

**Leading Cancer sites of Males**

1	C-42 HAEMATOPOIETIC & R.E. SYSTEM	349
2	C-34 BRONCHUS & LUNG	283
3	C-61 PROSTATE GLAND	206
4	C-15 ESOPHAGUS	201
5	C-32 LARYNX	201
6	C-77 LYMPH NODES	180
7	C-80 UNKNOWN PRIMARY SITES	149
8	C-20 RECTUM	144
9	C-06 MOUTH - OTHER & UNSPE: PARTS	109
10	C-16 STOMACH	104

## Classification by site of Malignancy

### Patients Registered in 2012

ICD-O code	Site of the Malignancy	Female	Male	Total
<b>C 00</b>	<b>LIP</b>		<b>11</b>	<b>11</b>
00.1	External lower lip		4	
00.6	Commissure of lip		6	
00.9	Lip, NOS		1	
<b>C 01</b>	<b>BASE OF TONGUE</b>	<b>4</b>	<b>73</b>	<b>77</b>
01.9	Base of tongue, NOS	4	73	
<b>C 02</b>	<b>TONGUE - OTHER &amp; UNSPECIFIED PARTS OF TOUNGE</b>	<b>29</b>	<b>99</b>	<b>128</b>
02.1	Border of tongue	5	21	
02.3	Ventral surface of tongue, NOS	2	2	
02.8	Overlapping lesion of tongue		2	
02.9	Tongue, NOS	22	74	
<b>C 03</b>	<b>GUM</b>	<b>10</b>	<b>22</b>	<b>32</b>
03.0	Upper gum	1	4	
03.1	Lower gum	2	8	
03.9	Gum, NOS	7	10	
<b>C 04</b>	<b>FLOOR OF MOUTH</b>	<b>5</b>	<b>44</b>	<b>49</b>
04.1	Lateral floor of mouth		1	
04.9	Floor of mouth, NOS	5	43	
<b>C 05</b>	<b>PALATE</b>	<b>8</b>	<b>48</b>	<b>56</b>
05.0	Hard palate	4	5	
05.1	Soft palate, NOS	2	31	
05.2	Uvula		5	
05.8	Overlapping lesion of palate		5	
05.9	Palate, NOS	2	2	
<b>C 06</b>	<b>OTHER &amp; UNSPECIFIED PARTS OF MOUTH</b>	<b>43</b>	<b>109</b>	<b>152</b>
06.0	Cheek mucosa	25	62	
06.1	Vestibule of mouth	1	1	
06.2	Retromolar area	1	18	
06.9	Mouth, NOS	16	28	
<b>C 07</b>	<b>PAROTID GLAND</b>	<b>30</b>	<b>24</b>	<b>54</b>
07.9	Parotid gland	30	24	
<b>C 08</b>	<b>OTHER &amp; UNSPECIFIED MAJOR SALIVARY GLANDS</b>	<b>3</b>	<b>5</b>	<b>8</b>
08.0	Submandibular gland	3	3	
08.9	Major salivary gland, NOS		2	

ICD-O code	Site of the Malignancy	Female	Male	Total
<b>C 09</b>	<b>TONSILS</b>	<b>5</b>	<b>76</b>	<b>81</b>
09.0	Tonsillar fossa		1	
09.1	Tonsillar pillar		2	
09.8	Overlapping lesion of tonsil		2	
09.9	Tonsil, NOS	5	71	
<b>C 10</b>	<b>OROPHARYNX</b>	<b>3</b>	<b>38</b>	<b>41</b>
10.0	Vallecula		20	
10.8	Overlapping lesion of oropharynx		1	
10.9	Oropharynx, NOS	3	17	
<b>C 11</b>	<b>NASOPHARYNX</b>	<b>9</b>	<b>9</b>	<b>18</b>
11.8	Overlapping lesion of nasopharynx	1		
11.9	Nasopharynx, NOS	8	9	
<b>C 12</b>	<b>PYRIFORM SINUS</b>	<b>8</b>	<b>61</b>	<b>69</b>
12.9	Pyriform sinus	8	61	
<b>C 13</b>	<b>HYPOPHARYNX</b>	<b>8</b>	<b>10</b>	<b>18</b>
13.0	Postcricoid region	8	3	
13.1	Hypopharyngeal aspect of Aryepiglottic fold		1	
13.2	Posterior wall of hypopharynx		1	
13.8	Overlapping lesion of hypopharynx		2	
13.9	Hypopharynx,NOS		3	
<b>C 14</b>	<b>OTHER &amp; ILL DEFINED SITES IN LIP, O. CAVITY &amp; PHARYNX</b>	<b>4</b>	<b>14</b>	<b>18</b>
14.0	Pharynx, NOS	4	14	
<b>C 15</b>	<b>ESOPHAGUS</b>	<b>141</b>	<b>201</b>	<b>342</b>
15.0	Cervical esophagus		2	
15.3	Upper third of esophagus	1		
15.4	Middle third of esophagus	54	63	
15.5	Lower third of esophagus	30	57	
15.8	Overlapping lesion of esophagus	3	7	
15.9	Oesophagus, NOS	53	72	
<b>C 16</b>	<b>STOMACH</b>	<b>33</b>	<b>104</b>	<b>137</b>
16.0	Cardia, NOS	12	42	
16.1	Fundus of stomach		1	
16.3	Gastric antrum	1	1	
16.4	Pylorus		2	
16.5	Lesser curvature of stomach, NOS		2	
16.6	Greater curvature of stomach, NOS		1	
16.8	Overlapping lesion of stomach		2	
16.9	Stomach, NOS	20	53	

ICD-O code	Site of the Malignancy	Female	Male	Total
<b>C 17</b>	<b>SMALL INTESTINE</b>	<b>1</b>	<b>6</b>	<b>7</b>
17.0	Duodenum		2	
17.1	Jejunum		1	
17.9	Small intestine, NOS	1	3	
<b>C 18</b>	<b>COLON</b>	<b>86</b>	<b>100</b>	<b>186</b>
18.0	Cecum	12	13	
18.1	Appendix	6	1	
18.2	Ascending colon	5	8	
18.3	Hepatic flexure of colon	2		
18.4	Transverse colon	3	10	
18.5	Splenic flexure of colon	1	4	
18.6	Descending colon	2	2	
18.7	Sigmoid colon	31	33	
18.9	Colon, NOS	24	29	
<b>C 19</b>	<b>RECTOSIGMOID JUNCTION</b>	<b>14</b>	<b>19</b>	<b>33</b>
19.9	Rectosigmoid junction	14	19	
<b>C 20</b>	<b>RECTUM</b>	<b>92</b>	<b>144</b>	<b>236</b>
20.9	Rectum, NOS	92	144	
<b>C 21</b>	<b>ANUS &amp; ANAL CANAL</b>	<b>13</b>	<b>10</b>	<b>23</b>
21.0	Anus, NOS	6	8	
21.8	Overlapping lesion of rectum, anus anal canal	7	2	
<b>C 22</b>	<b>LIVER &amp; INTRAHEPATIC BILE DUCT</b>	<b>20</b>	<b>60</b>	<b>80</b>
22.0	Liver	20	59	
22.1	Intrahepatic bile duct		1	
<b>C 23</b>	<b>GALL BLADDER</b>	<b>7</b>	<b>4</b>	<b>11</b>
23.9	Gallbladder	7	4	
<b>C 24</b>	<b>OTHER &amp; UNSPECIFIED PARTS OF BILIARY TRACT</b>	<b>16</b>	<b>14</b>	<b>30</b>
24.0	Extrahepatic bile duct	9	6	
24.1	Ampulla of Vater	5	5	
24.8	Overlapping lesion of biliary tract		3	
24.9	Biliary tract, NOS	2		
<b>C 25</b>	<b>PANCREAS</b>	<b>22</b>	<b>22</b>	<b>44</b>
25.0	Head of pancreas	7	9	
25.3	Pancreatic duct	1		
25.9	Pancreas, NOS	14	13	
<b>C 26</b>	<b>OTHER &amp; ILL DEFINED DIGESTIVE ORGANS</b>	<b>4</b>	<b>1</b>	<b>5</b>
26.0	Intestinal tract, NOS	2	1	
26.8	Overlapping lesion of digestive system	2		

ICD-O code	Site of the Malignancy	Female	Male	Total
<b>C 30</b>	<b>NASAL CAVITY AND MIDDLE EAR</b>	<b>6</b>	<b>9</b>	<b>15</b>
30.0	Nasal cavity	5	9	
30.1	Middle ear	1		
<b>C 31</b>	<b>ACCESSORY SINUSES</b>	<b>7</b>	<b>7</b>	<b>14</b>
31.0	Maxillary sinus	4	5	
31.1	Ethmoid sinus	2	2	
31.8	Overlapping lesion of accessory system	1		
<b>C 32</b>	<b>LARYNX</b>	<b>17</b>	<b>201</b>	<b>218</b>
32.0	Glottis	9	101	
32.1	Supraglottis	6	65	
32.2	Subglottis		1	
32.3	Laryngeal cartilage	1	8	
32.8	Overlapping lesion of larynx		3	
32.9	Larynx, NOS	1	23	
<b>C 33</b>	<b>TRACHEA</b>	<b>1</b>	<b>1</b>	<b>2</b>
33.9	Trachea	1	1	
<b>C 34</b>	<b>BRONCHUS &amp; LUNG</b>	<b>87</b>	<b>283</b>	<b>370</b>
34.0	Main bronchus		7	
34.1	Upper lobe, lung	4	18	
34.2	Middle lobe, lung		1	
34.3	Lower lobe, lung	2	7	
34.8	Overlapping lesion of lung	1		
34.9	Lung, NOS	80	250	
<b>C 37</b>	<b>THYMUS</b>	<b>6</b>	<b>8</b>	<b>14</b>
37.9	Thymus	6	8	
<b>C 38</b>	<b>HEART MEDIASTINUM &amp; PLEURA</b>	<b>6</b>	<b>22</b>	<b>28</b>
38.1	Anterior mediastinum	1	1	
38.2	Posterior mediastinum		3	
38.3	Mediastinum, NOS	5	15	
38.4	Pleura, NOS		3	
<b>C 39</b>	<b>OTHER &amp; ILLDEFINED SITES OF RES: SYSTEM &amp; IN: THOR ORG</b>	<b>2</b>		<b>2</b>
39.0	Upper respiratory tract	2		
<b>C 40</b>	<b>BONES, JOINTS AND ARTI: CARTILAGE OF LIMBS</b>	<b>20</b>	<b>19</b>	<b>39</b>
40.0	Long bones of upper limb, scapula & associated joints	2	2	
40.1	Short bones of upper limb		1	
40.2	Long bones of lower limb	17	16	
40.9	Bone of limb, NOS	1		

ICD-O code	Site of the Malignancy	Female	Male	Total
<b>C 41</b>	<b>BONES, JOINTS &amp; ARTI: CARTIL; OF OTHER &amp; UNSPE: SITES</b>	<b>5</b>	<b>11</b>	<b>16</b>
41.0	Bones of skull and face & associated joints	1	2	
41.2	Vertebral column		3	
41.3	Rib, Sternum, Clavicle & associated joints	2	2	
41.4	Pelvic bones, Sacrum, Coccyx & associated joints	2	3	
41.8	Overlapping lesion of bones, joints and articular cartilage		1	
<b>C 42</b>	<b>HAEMATOPOIETIC &amp; RET: ENDOTHELIAL SYSTEM</b>	<b>316</b>	<b>349</b>	<b>665</b>
42.1	Bone marrow	314	349	
42.2	Spleen	2		
<b>C 44</b>	<b>SKIN</b>	<b>26</b>	<b>53</b>	<b>79</b>
44.1	Eyelid	1	1	
44.2	External ear		5	
44.3	Skin, other & unspecified parts of face	5	4	
44.4	Skin of scalp and neck	4	4	
44.5	Skin of trunk	6	7	
44.6	Skin of upper limb and shoulder	2		
44.7	Skin of lower limb and hip	6	26	
44.9	Skin, NOS	2	6	
<b>C 47</b>	<b>PERIPHERAL NERVES, &amp; AUTONOMIC NERVOUS SYSTEM</b>	<b>3</b>	<b>1</b>	<b>4</b>
47.0	Per. nerves & A.N.S. of head, face, and neck	1	1	
47.2	Per. nerves & A.N.S. of lower limb and hip	2		
<b>C 48</b>	<b>RETROPERITONEUM &amp; PERITONEUM</b>	<b>11</b>	<b>8</b>	<b>19</b>
48.0	Retroperitoneum	4	6	
48.1	Specified parts of peritoneum	3	2	
48.2	Peritoneum, NOS	4		
<b>C 49</b>	<b>CONNECTIVE,SUBCUTANEOUS AND OTHER SOFT TISSUES</b>	<b>48</b>	<b>32</b>	<b>80</b>
49.0	Conn:Subcu: and other Soft tissues of head, face,	5	4	
49.1	Conn:Subcu: and other Soft tissues of upper limb,	11	5	
49.2	Conn:Subcu: and other Soft tissues of lower limb & hip	17	12	
49.3	Conn:Subcu: and other Soft tissues of thorax	3	2	
49.4	Conn:Subcu: and other Soft tissues of abdomen	4	2	
49.5	Conn:Subcu: and other Soft tissues of pelvis	6	6	
49.6	Conn:Subcu: and other Soft tissues of trunk	1		
49.9	Conn:Subcu: and other soft tissues, NOS	1	1	
<b>C 50</b>	<b>BREAST</b>	<b>1160</b>	<b>11</b>	<b>1171</b>
50.9	Breast, NOS	1160	11	
<b>C 51</b>	<b>VULVA</b>	<b>12</b>		<b>12</b>
51.0	Labium majus	1		
51.9	Vulva, NOS	11		

ICD-O code	Site of the Malignancy	Female	Male	Total
<b>C 52</b>	<b>VAGINA</b>	<b>8</b>		<b>8</b>
52.9	Vagina, NOS	8		
<b>C 53</b>	<b>CERVIX UTERI</b>	<b>471</b>		<b>471</b>
53.0	Endocervix	4		
53.1	Exocervix	1		
53.8	Overlapping lesion of cervix uteri	1		
53.9	Cervix uteri	465		
<b>C 54</b>	<b>CORPUS UTERI</b>	<b>180</b>		<b>180</b>
54.1	Endometrium	174		
54.2	Myometrium	1		
54.9	Corpus uteri	5		
<b>C 55</b>	<b>UTERUS, NOS</b>	<b>33</b>		<b>33</b>
55.9	Uterus, NOS	33		
<b>C 56</b>	<b>OVARY</b>	<b>357</b>		<b>357</b>
56.9	Ovary	357		
<b>C 57</b>	<b>OTHER &amp; UNSPECIFIED FEMALE GENITAL ORGANS</b>	<b>8</b>		<b>8</b>
57.0	Fallopian tube	6		
57.8	Overlapping lesion of female genital organs	1		
57.9	Female genital tract, NOS	1		
<b>C 58</b>	<b>PLACENTA</b>	<b>11</b>		<b>11</b>
58.9	Placenta	11		
<b>C 60</b>	<b>PENIS</b>		<b>23</b>	<b>23</b>
60.9	Penis, NOS		23	
<b>C 61</b>	<b>PROSTATE GLAND</b>		<b>206</b>	<b>206</b>
61.9	Prostate gland		206	
<b>C 62</b>	<b>TESTIS</b>		<b>30</b>	<b>30</b>
62.9	Testis, NOS		30	
<b>C 63</b>	<b>OTHER &amp; UNSPECIFIED MALE GENITAL ORGANS</b>		<b>7</b>	<b>7</b>
63.1	Spermatic cord		1	
63.2	Scrotum, NOS		5	
63.9	Male genital organs, NOS		1	
<b>C 64</b>	<b>KIDNEY</b>	<b>33</b>	<b>45</b>	<b>78</b>
64.9	Kidney, NOS	33	45	
<b>C 66</b>	<b>URETER</b>	<b>2</b>	<b>3</b>	<b>5</b>
66.9	Ureter	2	3	
<b>C 67</b>	<b>BLADDER</b>	<b>25</b>	<b>90</b>	<b>115</b>
67.3	Anterior wall of urinary bladder		1	
67.6	Ureteric orifice	1		
67.8	Overlapping lesion of bladder	1		
67.9	Bladder, NOS	23	89	

ICD-O code	Site of the Malignancy	Female	Male	Total
<b>C 68</b>	<b>OTHER &amp; UNSPECIFIED URINARY ORGANS</b>		<b>1</b>	<b>1</b>
68.0	Urethra		1	
<b>C 69</b>	<b>EYE AND ADENEXA</b>	<b>9</b>	<b>15</b>	<b>24</b>
69.2	Retina	6	9	
69.5	Lacrimal gland, NOS	2		
69.6	Orbit, NOS		2	
69.9	Eye, NOS	1	4	
<b>C 70</b>	<b>MENINGES</b>	<b>5</b>	<b>4</b>	<b>9</b>
70.0	Cerebral meninges		3	
70.9	Meninges, NOS	5	1	
<b>C 71</b>	<b>BRAIN</b>	<b>74</b>	<b>84</b>	<b>158</b>
71.0	Cerebrum	3		
71.1	Frontal lobe	9	14	
71.2	Temporal lobe	4	9	
71.3	Parietal lobe	10	16	
71.5	Ventricle, NOS		1	
71.6	Cerebellum, NOS	5	5	
71.7	Brain stem	8	4	
71.8	Overlapping lesion of brain	18	20	
71.9	Brain, NOS	17	15	
<b>C 72</b>	<b>SPINAL CORD, CRANIAL NERVES, &amp; OTHER PARTS OF CNS</b>	<b>2</b>	<b>5</b>	<b>7</b>
72.0	Spinal cord	2	3	
72.3	Optic nerve		1	
72.9	Nervous system, NOS		1	
<b>C 73</b>	<b>THYROID</b>	<b>442</b>	<b>95</b>	<b>537</b>
73.9	Thyroid gland	442	95	
<b>C 74</b>	<b>ADRENAL GLAND</b>	<b>13</b>	<b>12</b>	<b>25</b>
74.0	Cortex of adrenal gland	3	1	
74.1	Medulla of adrenal gland	4	2	
74.9	Adrenal gland, NOS	6	9	
<b>C 75</b>	<b>OTHER ENDOCRINE GLANDS &amp; RELATED STRUCTURES</b>	<b>4</b>	<b>1</b>	<b>5</b>
75.1	Pituitary gland	2	1	
75.2	Craniopharyngeal duct	1		
75.5	Aortic body and other paraganglia	1		

ICD-O code	Site of the Malignancy	Female	Male	Total
<b>C 76</b>	<b>OTHER &amp; ILL-DEFINED SITES</b>	<b>11</b>	<b>15</b>	<b>26</b>
76.0	Head, face or neck, NOS	2	6	
76.1	Thorax, NOS	1		
76.2	Abdomen, NOS	5	5	
76.3	Pelvis, NOS		3	
76.4	Upper limb, NOS	1		
76.5	Lower limb, NOS	1		
76.7	Other ill-defined sites	1	1	
<b>C 77</b>	<b>LYMPH NODES</b>	<b>118</b>	<b>180</b>	<b>298</b>
77.0	Lymph nodes of head, face and neck	37	64	
77.1	Intrathoracic lymph nodes	4	6	
77.2	Intra-abdominal lymph nodes	8	8	
77.3	Lymph nodes of axilla or arm	8	10	
77.4	Lymph nodes, inguinal region	10	17	
77.8	Lymph nodes of multiple regions	10	13	
77.9	Lymph node, NOS	41	62	
<b>C 80</b>	<b>UNKNOWN PRIMARY SITES</b>	<b>73</b>	<b>149</b>	<b>223</b>
80.9	Unknown primary site	73	149	
	<b>Total</b>	<b>4231</b>	<b>3308</b>	<b>7539</b>

### Distribution of malignancies by age groups

Age group	Female	Male	Total
Less than 1 year	14	19	33
Year 1 - 4	56	86	142
Year 5 - 16	103	112	215
Year 17 - 49	1331	659	1990
Year 50 - 69	2127	1769	3896
Year 70 - +	599	663	1262
	1		1
<b>Total Malignancies</b>	<b>4231</b>	<b>3308</b>	<b>7539</b>

## CIN 1, 11, & Uncertain Conditions

ICD-O	Site	Female	Male	Total
C 04	MOUTH - FLOOR		1	1
C 05	PALATE		1	1
C 06	MOUTH - OTHER & UNSPECIFIED PARTS	1	1	2
C 10	OROPHARYNX	1		1
C 14	OTHER & ILL DEFINED SITES IN LIP, O. CAVITY & PHARYNX		1	1
C 15	ESOPHAGUS	2	1	3
C 16	STOMACH		1	1
C 21	ANUS & ANAL CANAL		1	1
C 26	OTHER & ILL DEFINED DIGESTIVE ORGANS	1		1
C 31	ACCESSORY SINUSES		1	1
C 32	LARYNX		1	1
C 37	THYMUS	1	1	2
C 42	HAEMATOPOIETIC & RET: ENDO: SYSTEM	1	1	2
C 44	SKIN		1	1
C 49	CONNECTIVE,SUBCUTANEOUS AND OTHER SOFT TISSUES	1	1	2
C 50	BREAST	22	2	24
C 51	VULVA	1		1
C 53	CERVIX UTERI	7		7
C 55	UTERUS, NOS	2		2
C 56	OVARY	23		23
C 58	PLACENTA	5		5
C 67	BLADDER		1	1
C 70	MENINGES		1	1
C 71	BRAIN	2	9	11
C 72	SPINAL CORD, CRANIAL NERVES, & OTHER PARTS OF CNS	2	1	3
C 75	OTHER ENDOCRINE GLANDS & RELATED STRUCTURES	1	2	3
C 76	OTHER & ILL-DEFINED SITES	1	3	4
C 77	LYMPH NODES		2	2
	<b>Total</b>	<b>74</b>	<b>34</b>	<b>108</b>

## Leading Cancer sites by Sex & age group

### Female Age < 1 Year 14

C-22 Liver	4
C-69 Eye & Adnexa	3
C-64 Kidney	2
C-74 Adrenal gland	2
C-42 Hematopoietic & Reti:endo: system	1

### Male Age < 1 Year 19

C-42 Hematopoietic & Reti:endo: system	6
C-69 Eye & Adnexa	4
C-38 Heart, Mediastinum, & Pleura	2
C-22 Liver	1
C-44 Skin	1

### Female Age 1-4 Year Female 56

C-42 Hematopoietic & Reti:endo: system	28
C-49 Conn: Subcu: & other Soft tissues	5
C-64 Kidney	5
C-71 Brain	4
C-22 Liver	2

### Male Age 1-4 Year 86

C-42 Hematopoietic & Ret:endo: system	52
C-71 Brain	8
C-74 Adrenal gland	7
C-64 Kidney	5
C-69 Eye & Adnexa	3

### Female Age 5-16 Year 103

C-42 Hematopoietic & Reti:endo: system	44
C-71 Brain	17
C-40 Long bones of lower limb	7
C-56 Ovary	6
C-74 Adrenal gland	5

### Male Age 5-16 Year 112

C-42 Hematopoietic & Reti:endo: system	62
C-71 Brain	10
C-77 Lymph nodes	10
C-40 Bones, Joints & Arti: Cartilage of Limbs	8
C-49 Conn: Subcu: & Other Soft tissues	3

### Female Age 17-49 Year 1331

C-50 Breast	417
C-73 Thyroid gland	303
C-53 Cervix uteri	111
C-56 Ovary	111
C-42 Hematopoietic & Reti:endo: system	71

### Male Age 17-49 Year 659

C-42 Hematopoietic & Reti:endo: system	80
C-77 Lymph nodes	61
C-73 Thyroid gland	46
C-71 Brain	36
C-32 Larynx	30

### Female Age 50-69 Year 2127

C-50 Breast	618
C-53 Cervix uteri	288
C-56 Ovary	188
C-54 Corpus uteri	132
C-42 Hematopoietic & Reti:endo: system	124

### Male Age 50-69 Year 1769

C-34 Bronchus & Lung	190
C-15 Oesophagus	135
C-32 Larynx	134
C-42 Hematopoietic & Reti:endo: system	110
C-61 Prostate gland	106

### Female Age Year 70+ 599

C-50 Breast	124
C-53 Cervix uteri	72
C-56 Ovary	51
C-42 Hematopoietic & Reti:endo: system	48
C-15 Oesophagus	44

### Male Age Year 70+ 663


C-61 Prostate gland	96
C-34 Bronchus & Lung	65
C-42 Hematopoietic & Reti:endo: system	47
C-15 Oesophagus	42
C-32 Larynx	37

## INDOOR MORTALITY STATISTICS

	2009	2010	2011	2012
Total No of new Pts registered at NCI	11756	11576	12405	12552
Total No of Malignancies	8703	8224	8546	7539
Total Number of ward admissions	40522	43743	46714	49901
Total Number of hospital deaths	1689	1614	1781	1686
Death rate (as a percentage of admissions)	4.2%	3.7%	3.8%	3.4%

### Analysis of survived period of Patients registered in 2012

Out of pts registered in 2012, total number of Deaths occurred at NCI while taking treatment (up to 31 <sup>st</sup> of December 2013)	Female	Male	Total
No of pts died during the 1 <sup>st</sup> Quarter (0 - 90 days)	236	395	631
No of pts died during the 2 <sup>nd</sup> Quarter (91 - 180 days)	57	87	144
No of pts died during the 3 <sup>rd</sup> Quarter (181- 270 days)	42	54	96
No of pts died during the 4 <sup>th</sup> Quarter (271- 365 days)	27	29	56
No of pts Survived more than 365 days	37	25	62
<b>Total</b>	399	590	989



Distribution of death by number of days survived

## Sex Distribution and Leading Cancer sites of Patients died at NCIM

(Patients registered in 2012)

*No of Patients died at NCIM during the 1<sup>st</sup> 90 days - 631*

Sex	No	%
Male	395	62.6%
Female	236	37.4%
Total	631	100%

### Five leading causes of death in Females

Site of cancer	No	%
<b>C-42 Hematopoietic and R.E system</b>	57	24.2%
<b>C-56 Ovary</b>	28	11.9%
<b>C-50 Breast</b>	23	9.7%
<b>C-15 Oesophagus</b>	14	5.9%
<b>C-53 Cervix uteri</b>	14	5.9%

### Five leading causes of death in Males

Site of cancer	No	%
<b>C-42 Hematopoietic and R.E system</b>	63	15.9%
<b>C-34 Bronchus &amp; Lung</b>	61	15.4%
<b>C-15 Oesophagus</b>	41	10.4%
<b>C-80 Unknown primary site</b>	34	8.6%
<b>C-16 Stomach</b>	18	4.6%

### Deaths by age group

	< 1 Year	1-4 Years	5-16 Years	17-49 Years	50-69 Years	70+ Years	<i>Total</i>
Male		4	5	53	239	94	395
Female	3	4	4	48	127	50	236
Total	3	8	9	101	366	144	631

## Sex Distribution and Leading Cancer sites of Patients died at NCIM

(Patients registered in 2012)

**No of Patients died at NCIM during the 2<sup>nd</sup> 90 days (91- 180 days) - 144**

Sex	No	%
Male	87	60.4%
Female	57	39.6%
Total	144	100%

### Five leading causes of death in Females

Site of cancer	No	%
<b>C-42 Hematopoietic and R.E system</b>	14	24.6%
<b>C-50 Breast</b>	7	12.3%
<b>C-34 Bronchus &amp; Lung</b>	5	8.8%
<b>C-77 Lymph nodes</b>	5	8.8%
<b>C-49 Conn; Subcu; &amp;Other Soft tissues</b>	3	5.3%

### Five leading causes of death in Males

Site of cancer	No	%
<b>C-34 Bronchus &amp; Lung</b>	14	16.1%
<b>C-42 Hematopoietic and R.E system</b>	11	12.6%
<b>C-15 Oesophagus</b>	10	11.5%
<b>C-80 Unknown primary site</b>	8	9.2%
<b>C-05 Palate</b>	4	4.6%

### Deaths by age group

	<b>&lt; 1 Year</b>	<b>4-Jan Years</b>	<b>16-May Years</b>	<b>17-49 Years</b>	<b>50-69 Years</b>	<b>70+ Years</b>	<b>Total</b>
Male	1	1	4	13	50	18	87
Female		2	3	18	29	5	57
Total	1	3	7	31	79	23	144

## Sex Distribution and Leading Cancer sites of Patients died at NCIM

(Patients registered in 2012)

**No of Patients died at NCIM during the 3<sup>rd</sup> 90 days (181- 270 days) - 96**

Sex	No	%
Male	54	56.3%
Female	42	43.7%
Total	96	100%

### Five leading causes of death in Females

Site of cancer	No	%
<b>C-50 Breast</b>	7	16.7%
<b>C-42 Hematopoietic and R.E system</b>	6	14.3%
<b>C-20 Rectum</b>	4	9.5%
<b>C-53 Cervix uteri</b>	3	7.1%
<b>C-15 Oesophagus</b>	2	4.8%

### Five leading causes of death in Males

Site of cancer	No	%
<b>C-02 Tongue- Other &amp; Unsp; parts</b>	8	14.8%
<b>C-42 Hematopoietic and R.E system</b>	6	11.1%
<b>C-06 Mouth - Other &amp; Unsp; parts</b>	4	7.4%
<b>C-10 Oropharynx</b>	3	5.6%
<b>C-12 Pyriform sinus</b>	3	5.6%

### Deaths by age group

	< 1 Year	1- 4Year	5-16 Year	17-49 Year	50-69 Year	70+ Year	Total
Male	1		1	11	34	7	54
Female		1	4	15	16	6	42
Total	1	1	5	26	50	13	96

## Sex Distribution and Leading Cancer sites of Patients died at NCIM

(Patients registered in 2012)

**No of Patients died at NCIM during the 4<sup>th</sup> 90 days (271- 365 days) - 56**

Sex	No	%
Male	29	51.8%
Female	27	48.2%
Total	56	100%

### Five leading causes of death in Females

Site of cancer	No	%
<b>C-42 Hematopoietic and R.E system</b>	6	22.2%
<b>C-53 Cervix uteri</b>	5	18.5%
<b>C-20 Rectum</b>	3	11.1%
<b>C-34 Bronchus &amp; Lung</b>	2	7.4%
<b>C-50 Breast</b>	2	7.4%

### Five leading causes of death in Males


Site of cancer	No	%
<b>C-06 Mouth - Other &amp; Unsp; parts</b>	4	13.8%
<b>C-34 Bronchus &amp; Lung</b>	3	10.3%
<b>C-04 Floor of mouth</b>	2	6.9%
<b>C-15 Oesophagus</b>	2	6.9%
<b>C-16 Stomach</b>	2	6.9%

### Deaths by age group

	< 1 Year	1- 4Year	5-16 Year	17-49 Year	50-69 Year	70+ Year	Total
Male		1	2	5	17	4	29
Female		1	2	11	11	2	27
Total		2	4	16	28	6	56

**Cancer Patients reported to**  
**National Cancer Institute in 2012 by Districts**

District	Female	Male	Total
Ampara	47	32	79
Anuradapura	73	42	115
Badulla	69	43	112
Batticaloa	46	32	78
Colombo	994	824	1818
Galle	111	60	171
Gampaha	910	710	1620
Hambantota	59	42	101
Jaffna	36	13	49
Kalutara	449	353	802
Kandy	75	54	129
Kegalle	139	161	300
Kilinochchi	6	5	11
Kurunagala	278	237	515
Mannar	3	2	5
Matale	25	29	54
Matara	82	44	126
Monaragala	51	28	79
Mulaitivu	6	2	8
NuwaraEliya	25	22	47
Polonnaruwa	43	32	75
Puttalam	233	189	422
Rathnapura	250	170	420
Trincomalee	20	11	31
Vavuniya	13	4	17
NA	188	167	355
<b>Total</b>	<b>4231</b>	<b>3308</b>	<b>7539</b>



**Cancer patients reported to NCI during last three years by District**

<b>Province</b>	<b>District</b>	<b>2012</b>	<b>2011</b>	<b>2010</b>
<b>Central</b>	Kandy	129	152	126
	Matale	54	60	50
	NuwaraEliya	47	68	65
<b>Estern</b>	Ampara	79	98	94
	Batticaloa	78	65	126
	Trincomalee	31	46	55
<b>Nothern</b>	Jaffna	49	23	40
	Kilinochchi	11	6	8
	Mannar	5	11	15
	Mulaitivu	8	2	5
	Vavuniya	17	20	39
<b>North Central</b>	Anuradapura	115	142	169
	Polonnaruwa	75	84	69
<b>North Central</b>	Kurunagala	515	615	564
	Puttalam	422	516	457
<b>Sabaragamuwa</b>	Kegalle	300	321	331
	Rathnapura	420	467	475
<b>Southern</b>	Galle	171	179	184
	Hambanthota	101	133	140
	Matara	126	145	155
<b>Uva</b>	Badulla	112	126	131
	Monaragala	79	107	60
<b>Western</b>	Colombo	1818	2148	2117
	Kalutara	802	992	878
	Gampaha	1620	1802	1721
	District N.A	355	189	150
<b>Total</b>		<b>7539</b>	<b>8517</b>	<b>8224</b>